The IMbrave150 trial evaluated the combination of atezolizumab and bevacizumab (VEGF inhibitor) compared with sorafenib among 501 randomized patients with advanced HCC and preserved liver function. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.